Shire
CompanyUnited StatesROR
Shire develops one asset, approved (dexamethasone in burns). Mostly small molecule acting on NF-κB signalling, apoptosis and NR3C1; based in the United States.
- Assets
- 1
- Furthest
- Approved
- Trials
- 6
- Signals
- 0
Pipeline
1Glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive effects
ApprovedSmall moleculeNF-κB signallingApoptosisburnsConjunctivitis, Allergic
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms5
- Trials14
- Signals1
- Similar companies6
Updated 7 Oct 2026 · 71 sources